Healthpeak Q2 2026 Beat-and-Raise Signals Resilience; Guidance Increased

What happened

Healthpeak Properties reported Q2 2026 FFO as Adjusted of $0.46 per share, matching Street expectations, while net income was $0.08 per share. The company executed 1.6 million square feet of outpatient medical and lab leases, underscoring robust demand in its core segments. Management raised full-year 2026 earnings guidance, reflecting confidence that outpatient and CCRC strength is offsetting lingering lab softness. The results suggest lab occupancy may be stabilizing after prior impairments, and the dividend remains well-covered with an AFFO payout ratio near 71%. This print reinforces the base-to-bull case for Healthpeak, implying that the stock’s discounted valuation at approximately 9x forward FFO is overly cautious.

Implication

Investors should see Q2 2026 results as evidence that outpatient and CCRC demand remain robust, and that lab leasing is recovering, reducing the risk of prolonged earnings deterioration. The FFO as Adjusted of $0.46 per share covers the quarterly dividend with a wide margin, supporting dividend safety. With management raising full-year guidance, the stock’s valuation at approximately 9x forward FFO appears undemanding relative to healthcare REIT peers. However, caution remains warranted given the potential for interest rates to stay higher for longer and possible lab oversupply in certain markets. Over the next 12 months, continued execution on leasing and asset sales could narrow the discount to fair value, targeting a total return in the mid-teens.

Thesis delta

The Q2 2026 beat-and-raise strengthens the investment thesis by confirming that outpatient/CCRC growth engines are firing and lab headwinds are manageable. This shifts probability weight slightly from the bear case toward the bull case, with higher confidence that total same-store NOI can reaccelerate. The thesis now emphasizes the undervaluation of stable cash flows, with limited downside from current levels given strong dividend coverage and asset backing.